期刊文献+

莪术油纳米脂质载体给药系统的制备及其评价 被引量:23

Preparation and Evaluation of Zedoary Turmeric Oil Nanostructuded Lipid Carriers Delivery Systems
下载PDF
导出
摘要 目的研制莪术油纳米脂质载体系统。方法采用熔融超声-低温固化法制备莪术油纳米质脂载体系统,考察载药纳米粒的形态、粒径、Zeta电位等理化性质;用HPLC测定药物的包封率及体外释放特性;采用肝内隧道植入法,在小鼠H-22移植瘤模型上观察两种莪术油制剂的体内抑瘤活性。结果制得的纳米粒在透射电镜下均呈圆球形,平均粒径为(82·26±3·63)nm,Zeta电位为-(23·53±1·29)mV,制剂中吉玛酮的质量浓度为(0·972±0·021)g·L-1,包封率为(94·95±1·87)%。结论熔融超声-低温固化法应用于莪术油等挥发油类药物纳米分散给药系统的制备是可行的,对小鼠体内H-22肉瘤株有显著的抑制效果。 OBJECTIVE To investigate the preparation of zedoary turmeric oil nanostructured lipid carriers(ZTO-NLC).METHODS ZTO- NLC were prepared using the hot dispersion-cool solidification method. The morphology, mean diameter (MD) and Zeta potential of ZTO- NLC were used to evaluate the influence of different formulation and preparation factors;the contents of dispersion and entrapment efficiency of ZTO-NLC were determined by HPLC.Orthotopic transplation tumor model of hepatoma in mice were used to observe the inhibitory effects of zedoary turmeric oil on H-22 cellsin vivo.RESULTS The ZID-NLC in electron microscopy were spherical in shape, the mean diameter of ZTO-NLC was (82.26 ± 3.63)nm, Zeta potential was - (23.53 ± 1.29)mV,the content of Germacrone was (0.972 ± 0.021)g·L^-1, the encapsulation efficiency of Germacrone was (94.95 ±1.87)%, and the microspheres were in good shape. CONCLUSION It is able to prepare nano-delivery system with volatiable oil,such as zedoary turmeric oil,by hot dispersion-cool solidification method. ZTO-NLC has marked inhibitory effects on mice H-22 cells in vivo.
出处 《中国药学杂志》 CAS CSCD 北大核心 2006年第24期1881-1884,共4页 Chinese Pharmaceutical Journal
关键词 莪术油 纳米脂质载体系统 熔融超声-低温固化法 药效学 zedoary turmeric oil nanostructured lipid carriers hot dispersion-cool solidification method pharmacodynamics
  • 引文网络
  • 相关文献

参考文献13

  • 1TIAN N X, TU P F. Research and Prospect of the Mozeria Medica(药物学研究与展望)[M].Beijing: Science Press,1999:116-118.
  • 2..Ch. P(2005) VolⅡ(中国药典2005年版.二部)[S]..,,2005..591-592..
  • 3施广霞,于丽华,刘金友,郭连英,邢嵘,马学真,钱振超.β─榄香烯抗肿瘤作用的实验研究──I β─榄香烯体外对L615白血病细胞直接作用的实验研究[J].大连医学院学报,1994,16(2):137-140. 被引量:29
  • 4MULLER R H,MADER K, GOHLA S. Solid lipid nanoparticles (SLN) for controlled drug delivety-a review of the state of art[J] .Eur J Pharm Biopharm, 2000,50:161-177.
  • 5WLFANG M, KAIAIEN M. Solid lipid nanoparticles production characterization and applications[J]. Adv Drug Deli Revs,2001, 47:165-196.
  • 6YANG S C, ZHU J B, LU Y. Body distribution of camptothecin solid lipid nanoparticles after oral adminiatratian[J]. Pharm Res, 1999, 16(5) :751.
  • 7RAINER H M, CORNELIA M K. Challenges and solutions for the delivery of biotech drugs a review of drug nanocrystal technology and lipid nanoparticles[J]. J Biotechnol,2004,113:151-170.
  • 8WISSING S A, KAYSER O, MUTLLER R H. Solid lipid nanoparticles for parenteral drug delivery [J]. Adv Drug Deliv Rev ,2004,56:1257-1272.
  • 9MULLER R H, RADTKE M, WISSING S A. Nanostructured lipid matrices for improved microen-capsulation of drugs [J]. Int J Pharm, 2002,342(1-2) : 121-128.
  • 10MARCOS G F, MARIA J A, DOLORES T. Design and characterization of a new drug nanocarrier made from solid liquid lipid mixtures[J]. J Interface Sci,2005,285:590-598.

二级参考文献9

  • 1彭宝冈,中山医科大学学报,1997年,17卷,增刊,7页
  • 2梁力建,中华肿瘤杂志,1996年,3期,21页
  • 3Levy MY, Benita S. Drug release from submicronized O/W emulsion :a new in vitro kinetic evaluation model[J]. Int J Pharm, 1990,66:29-37.
  • 4Santos Magatlhaes NS, Cave G, Seiller M, et al. The stability and in vitro release kinetics of a clofibride emulsion [J]. Int J Pharm, 1991,76:225 - 237.
  • 5程一櫂,黄敏,王明俭,郑怀祖,袁保和,许广源,钱振超,程佳.615系小鼠乳腺癌细胞系(Ca761/L)的建立及其生物学特性[J]大连医学院学报,1987(02).
  • 6钱振超,刘金友,赵肃荣,于丽华,张德玉,魏文汉.莪术瘤苗的主动免疫保护效应——莪术抗癌作用原理的探讨[J]药学学报,1981(12).
  • 7王长虹.乳剂的缓释和控释作用研究进展[J].国外医学(药学分册),1997,24(5):300-304. 被引量:10
  • 8王长虹,孙殿甲,苗爱东,王本富.甲苯咪唑水包油型口服乳剂的药物释放[J].中国医院药学杂志,2000,20(1):7-9. 被引量:2
  • 9陈大兵,吕万良,杨天智,李静,张强.紫杉醇表面修饰脂质纳米粒的制备和性质[J].北京大学学报(医学版),2002,34(1):57-60. 被引量:18

共引文献49

同被引文献332

引证文献23

二级引证文献143

;
使用帮助 返回顶部